Compugen Ltd. (CGEN) स्टॉक विश्लेषण

कंपनी का अवलोकन

Compugen Ltd. operates as a clinical-stage therapeutic discovery and development entity focused on the research, development, and commercialization of therapeutics and product candidates across Israel, the United States, and Europe. The company functions within the Healthcare sector and specifically the Biotechnology industry, a domain characterized by high R&D expenditures and the pursuit of novel medical treatments. Its current scale is defined by a market capitalization of $235.53M and a trailing twelve-month revenue of $72.76M, supported by a workforce of 75 employees. These financial figures indicate a mid-cap biotechnology enterprise that maintains a significant valuation relative to its current revenue base, suggesting the market assigns a high premium to its clinical pipeline potential and future commercial prospects rather than immediate profitability.

वित्तीय स्वास्थ्य

The company reported a revenue of $72.76M for the trailing twelve months, generating a net income of $35.34M and an EBITDA of $31.80M. The substantial gap between the $72.76M revenue and the $35.34M net income reveals an exceptionally efficient cost structure, as the company retains a vast majority of its top-line earnings after tax and operating expenses. Free cash flow stands at $24.33M, which provides the company with robust financial flexibility to fund its clinical-stage programs without needing to raise external capital. The gross margin is recorded at 87.3%, indicating that the company retains a large portion of revenue from its sales before accounting for operating costs. The operating margin is 83.2%, while the profit margin is 48.6%, collectively demonstrating that the company's operational overhead is minimal relative to its sales volume. In terms of liquidity, the company holds $145.64M in cash against a debt load of only $2.96M, resulting in a debt-to-equity ratio of 2.88 and a conservative balance sheet despite the high debt-to-equity figure reflecting the accounting method of equity dilution in biotech. The current ratio is 6.56, which indicates that the company possesses ample current assets to cover its short-term liabilities with a very high safety margin. Return on Equity is 44.8% and Return on Assets is 14.4%, metrics that reveal highly effective management in utilizing shareholder equity and total assets to generate substantial returns.

मूल्यांकन आकलन

The trailing twelve-month P/E ratio is 6.53, whereas the forward P/E is -7.44, implying that the market expects earnings to be negative in the coming year due to anticipated investments in the clinical pipeline. The price-to-book ratio is 2.28, indicating that the market values the company at a premium of 128% over its tangible book value, a common feature for asset-light biotechnology firms. The price-to-sales ratio is 3.24 and the EV/EBITDA is 2.89, suggesting that the company is valued significantly on its revenue generation and cash flow potential rather than current earnings power. The stock has traded between a 52-week low of $1.13 and a 52-week high of $2.49, placing the current trading position within a range that reflects high volatility typical of clinical-stage assets. The beta value is 2.77, which signifies that the stock price is nearly three times more volatile than the broader market, exposing investors to amplified market movements.

Growth & Income

Revenue growth year-over-year is an extraordinary 4477.3%, while earnings growth is marked as N/A due to the specific accounting treatment or timing of one-time events affecting the net income calculation. The absence of earnings growth data compared to the massive revenue expansion implies that the company is prioritizing scaling revenue through new product launches or partnerships rather than optimizing bottom-line profitability in the current period. As the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings to reinvest into its research and development pipeline. The overall growth and income profile is characterized by aggressive revenue scaling with no current income distribution, reflecting a classic growth-stage biotechnology investment strategy focused entirely on clinical advancement.